Allergy Therapeutics (LON:AGY) Stock Price Down 7% – Here’s Why

Allergy Therapeutics plc (LON:AGY) shares traded down 7% during trading on Wednesday . The stock traded as low as GBX 5.73 ($0.08) and last traded at GBX 6 ($0.08). 178,716 shares were traded during mid-day trading, a decline of 54% from the average session volume of 386,971 shares. The stock had previously closed at GBX 6.45 ($0.08).

Allergy Therapeutics Stock Down 4.0 %

The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63. The firm has a market capitalization of £294.90 million, a P/E ratio of -5.78, a P/E/G ratio of -30.70 and a beta of 1.40. The stock has a fifty day moving average price of GBX 6.54 and a two-hundred day moving average price of GBX 5.95.

Allergy Therapeutics (LON:AGY) last released its earnings results on Monday, March 31st. The company reported GBX (0.23) ($0.00) earnings per share for the quarter. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%. Research analysts forecast that Allergy Therapeutics plc will post -2.56 EPS for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.